A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13 (TM) in Healthy Infants [Estudio multicentrico y doble ciego de la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna antineumococica conjugada (V114) en comparacion con Prevenar 13 (TM) en lactantes sanos]

Next Previous
Trial Profile

A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13 (TM) in Healthy Infants [Estudio multicentrico y doble ciego de la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna antineumococica conjugada (V114) en comparacion con Prevenar 13 (TM) en lactantes sanos]

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2012

At a glance

  • Drugs Aluminium compounds; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal-15-valent-vaccine-conjugate
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 15 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jul 2012 Pfizer added as associations as reported in the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top